Sunday, October 1

6:00 p.m.-8:00 p.m. OPENING KEYNOTE ADDRESSES AND SPECIAL LECTURE
Salons EF

6:00 p.m.-6:45 p.m. Principles of response and resistance to immunotherapy
Levi A. Garraway, Eli Lilly and Company, Indianapolis, IN

6:45 p.m.-7:30 p.m. Engineering T cells to eradicate tumors in the age of synthetic biology
Philip D. Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA

7:30 p.m.-8:00 p.m. Immune checkpoint blockade in cancer therapy: New Insights, opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

8:00 p.m.-9:30 p.m. OPENING RECEPTION
Back Bay

Monday, October 2

7:00 a.m.-8:15 a.m. BREAKFAST AND MENTORING ROUNDTABLES
Fairfield-Arlington

8:15 a.m.-9:45 a.m. SESSION 1: SINGLE-CELL IMAGING OF CANCER IMMUNOLOGY
Salons EF
Session Chair: Matthew F. Krummel, University of California San Francisco, San Francisco, CA

8:15 a.m.-8:45 a.m. Pathology from the molecular scale on up
Garry P. Nolan, Stanford University, Stanford, CA

8:45 a.m.-9:15 a.m. Tracking immune cells in sterile injury and how it pertains to cancer
Paul Kubes, University of Calgary, Calgary, AB, Canada

9:15 a.m.-9:45 a.m. Imaging- and single cell-based insights into effective antitumor immune responses
Matthew F. Krummel

9:45 a.m.-10:15 a.m. BREAK
Salons EF Foyer

*Short talk from proffered abstract
CONFERENCE PROGRAM

10:15 a.m.-12:00 p.m.  SESSION 2: SYNTHETIC IMMUNOTHERAPY
Salons EF
Session Chair: Darrell J. Irvine, Koch Institute of MIT, Cambridge, MA

10:15 a.m.-10:45 a.m.  Enhancing combination immunotherapy and adoptive cell therapy of cancer via lymph node-targeted vaccines
Darrell J. Irvine

10:45 a.m.-11:15 a.m.  Genetic engineering of therapeutic T cells using synthetic nanoparticles
Matthias T. Stephan, Fred Hutchinson Cancer Research Center, Seattle, WA

11:15 a.m.-11:45 a.m.  Engineering T cells to resist and convert immunosuppressive tumor microenvironments
Yvonne Y. Chen, University of California Los Angeles, Los Angeles, CA

11:45 a.m.-12:00 p.m.  Targeting multiple myeloma with universal SLAMF7-specific CAR T-cells*
Rohit Mathur, The University of Texas MD Anderson Cancer Center, Houston, TX

12:00 p.m.-1:30 p.m.  LUNCH ON OWN/FREE TIME

1:30 p.m.-3:15 p.m.  SESSION 3: NEOANTIGENS: THE NEW BIOMARKERS
Salons EF
Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA

1:30 p.m.-2:00 p.m.  RiboSeq and ye shall find: Noncanonical protein translation in cancer immunosurveillance
Jonathan W. Yewdell, National Institute of Allergy and Infectious Diseases, Bethesda, MD

2:00 p.m.-2:30 p.m.  Cell transfer immunotherapy targeting unique somatic mutations in cancer
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

2:30 p.m.-3:00 p.m.  Developing and improving personalized neoantigen-targeting cancer vaccines
Catherine J. Wu

3:00 p.m.-3:15 p.m.  Identification of breast cancer neoantigens exposed by radiation therapy*
Claire Lhuillier, Weill Cornell Medical College, New York, NY

3:15 p.m.-3:45 p.m.  BREAK
Salons EF Foyer

3:45 p.m.-5:30 p.m.  SESSION 4: A SYSTEMS APPROACH TO IMMUNO-ONCOLOGY
Salons EF
Session Chair: Dana Pe’er, Sloan Kettering Institute, New York, NY

3:45 p.m.-4:15 p.m.  Integrative genomics and immune contexture approach to immune-oncology
Jérôme Galon, French National Institute of Health and Medical Research, Paris, France

*Short talk from proffered abstract
4:15 p.m.-4:45 p.m.  
*Short talk from proffered abstract  
**Spatio-temporal quirks of IFN-γ regulation of immune responses in tumors**  
Grégoire Altan-Bonnet, National Cancer Institute, Bethesda, MD

4:45 p.m.-5:15 p.m.  
**An atlas of the tumor immune ecosystem**  
Dana Pe’er

5:15 p.m.-5:30 p.m.  
**Genetic mechanisms of immune evasion in colorectal cancer**  
Marios Giannakis, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

5:30 p.m.-7:30 p.m.  
POSTER SESSION A/RECEPTION  
Back Bay

---

**Tuesday, October 3**

7:00 a.m.-8:00 a.m.  
**BREAKFAST AND NETWORKING ROUNDTABLES**  
Fairfield-Arlington

8:00 a.m.-9:45 a.m.  
**SESSION 5: THE INFLAMMATORY TUMOR MICROENVIRONMENT**  
Salons EF  
**Session Chair: Miriam Merad,** Icahn School of Medicine at Mount Sinai, New York, NY

8:00 a.m.-8:30 a.m.  
**Immune cell atlas of human lung cancer lesions**  
Miriam Merad

8:30 a.m.-9:00 a.m.  
**Macrophages orchestrate early dissemination and metastasis**  
Julio A. Aguirre-Ghiso, Icahn School of Medicine at Mount Sinai, New York, NY

9:00 a.m.-9:30 a.m.  
**Stromal microenvironments in cancer immunology**  
Shannon J. Turley, Genentech, Inc., San Francisco, CA

9:30 a.m.-9:45 a.m.  
**Lymph node colonization promotes systemic tumor metastasis through induction of immune tolerance**  
Nathan E. Reticker-Flynn, Stanford University, Stanford, CA

9:45 a.m.-10:00 a.m.  
**Preventing the recurrence of breast cancer at the metastatic niche using resolution-phase macrophages**  
Dalit Barkan, University of Haifa, Haifa, Israel

10:00 a.m.-10:30 a.m.  
**BREAK**  
Salons EF Foyer

*Short talk from proffered abstract*
CONFERENCE PROGRAM

10:30 a.m.-12:00 p.m.  
**SESSION 6: ENGINEERING IMMUNE CELLS TO TREAT CANCER**  
Salons EF  
**Session Chair: Carl H. June**, University of Pennsylvania, Philadelphia, PA

10:30 a.m.-11:00 a.m.  
**CAR therapy: Beyond the CD19 paradigm**  
Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

11:00 a.m.-11:30 a.m.  
**New directions in T cell therapies for cancer**  
Marcela V. Maus, Massachusetts General Hospital, Cancer Center, Boston, MA

11:30 a.m.-12:00 p.m.  
**Updates on CAR T cells**  
Carl H. June

12:00 p.m.-2:30 p.m.  
**POSTER SESSION B/LUNCH**  
Back Bay

2:30 p.m.-4:30 p.m.  
**SESSION 7: THE MICROBIOME IN CANCER IMMUNITY**  
Salons EF  
**Session Chair: Giorgio Trinchieri**, National Cancer Institute, Bethesda, MD

2:30 p.m.-3:00 p.m.  
**Cancer and the microbiome**  
Giorgio Trinchieri

3:00 p.m.-3:30 p.m.  
**Fusobacterium nucleatum and colon cancer**  
Wendy S. Garrett, Harvard T.H. Chan School of Public Health, Boston, MA

3:30 p.m.-4:00 p.m.  
**Understanding response and resistance to cancer therapy: Lessons learned from melanoma**  
Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, TX

4:00 p.m.-4:15 p.m.  
**Drugging the human microbiome for combination with tumor immunotherapy***  
David N. Cook, Seres Therapeutics, Cambridge, MA

4:15 p.m.-4:30 p.m.  
**Fusobacterium species, microsatellite instability, and exome-wide neoantigen load in relation to immune response to colorectal cancer***  
Shuji Ogino, Brigham and Women’s Hospital, Boston, MA

4:30 p.m.-4:45 p.m.  
**BREAK**  
Salons EF Foyer

*Short talk from proffered abstract
**SESSION 8: METABOLIC REGULATION OF IMMUNE RESPONSES**

Salons EF


4:45 p.m.-5:15 p.m.  
*Krebs cycle reprogrammed for cytokines*  

5:15 p.m.-5:45 p.m.  
*Identification of essential genes for cancer immunotherapy*  
Nicholas P. Restifo, National Cancer Institute, Bethesda, MD

5:45 p.m.-6:15 p.m.  
*Immunometabolic circuits in myeloid cell reprogramming*  
Mihai Netea, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

6:15 p.m.-6:30 p.m.  
*Metabolic adaptations establish immunotherapy resistance in melanoma*  
Ashvin R. Jaiswal, The University of Texas MD Anderson Cancer Center, Houston, TX

---

**Wednesday, October 4**

**7:00 a.m.-8:00 a.m.**  
*BREAKFAST*  
Fairfield-Arlington

**8:00 a.m.-9:45 a.m.**  
**SESSION 9: NEW COMBINATION THERAPIES**  
Salons EF

**Session Chair: Sandra Demaria**, Weill Cornell Medical College, New York, NY

8:00 a.m.-8:30 a.m.  
*Strategies to optimize the adjuvant role of radiotherapy during cancer immunotherapy*  
Silvia C. Formenti, Weill Cornell Medical College, New York, NY

8:30 a.m.-9:00 a.m.  
*Cancer immunotherapy: Translational control of immune checkpoint*  
Caroline Robert, Institut de Cancerologie Gustave Roussy, Villejuif, France

9:00 a.m.-9:30 a.m.  
*Novel insights into the dose-dependency of radiation immunogenicity*  
Sandra Demaria

9:30 a.m.-9:45 a.m.  
*Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies*  
Elizabeth E. Evans, Vaccinex, Rochester, NY  
*not eligible for CME credit*

**9:45 a.m.-10:15 a.m.**  
*BREAK*  
Salons EF Foyer

*Short talk from proffered abstract*
CONFERENCE PROGRAM

10:15 a.m.-11:30 a.m.  SESSION 10: CHECKPOINTS AND IMMUNOMODULATION
Salons EF
Session Chair: Joshua D. Brody, Icahn School of Medicine at Mount Sinai, New York, NY

10:15 a.m.-10:45 a.m.  Regulatory T cells and radiation therapy
Charles G. Drake, Columbia University Medical Center, New York, NY

10:45 a.m.-11:15 a.m.  Improving checkpoint blockade for lymphoma with Flt3L-primed in situ vaccination
Joshua D. Brody

11:15 a.m.-11:30 a.m.  Cancer-germline antigens discriminate clinical outcome to CTLA4 blockade*
Sachet Shukla, Dana-Farber Cancer Institute, Boston, MA

11:30 a.m.  CLOSING REMARKS AND DEPARTURE
Salons EF

*Short talk from proffered abstract